Miura Partners to acquire HealthTech BioActives from The Riverside Company.

Miura Partners, a private equity firm, agreed to acquire HealthTech BioActives, a developer of food supplements for the prevention of cognitive impairment, from The Riverside Company, a global investment firm. Financial terms were not disclosed. “Our divestment of HTBA is the latest example of Riverside’s commitment to growing and supporting mid-market companies that show high growth potential and sound management. This is our fifth completed investment in the specialty ingredients space in Europe, an industry in which Riverside has a lengthy track record and a global network of expertise. HTBA demonstrates Riverside’s ability to lead businesses through challenging macroeconomic environments to deliver consistent value for our portfolio companies,” Rafael Alvarez-Novoa, Riverside Europe Partner.